Semaglutide

A GLP‑1 receptor agonist with proven ASCVD benefit and strong weight loss is a great candidate drug for patients with cardiovascular disease and obesity. However, it is preferred for HFpEF and it has not been shown to reduce HFrEF hospitalization. It may be added later for weight or ASCVD risk, but it does not replace another cardioprotective drug for HF benefit as a first step.

  • Sitagliptin [undo]
  • DNA Ligase [undo]
  • Dapagliflozin [undo]
  • Joins an online support group. She does not want to see a therapist. [undo]
  • 37 °C, niveles atmosféricos de O₂, niveles atmosféricos de CO₂ [undo]
  • Exenatide [undo]
  • Use alcohol to soothe her pain [undo]
  • Pentru a ne proteja de orice scurgeri. Albul este o culoare în care cele mai multe scurgeri sunt vizibile, în funcție de culoarea soluției [undo]
  • Serum sodium [undo]
  • Adverse effect due to heparin [undo]
  • Ανάλυση λίθων και πλήρης μεταβολικός έλεγχος [undo]
  • Ask the patient to walk or change position (risk of falling). [undo]
  • LB [undo]
  • Temporarily stop taking metformin [undo]
  • Descrierea 3 [undo]
  • Οφθαλμολογική Εξέταση [undo]
  • MSA [undo]
  • Chlorpropamide [undo]
  • Isosorbide mononitrate (organic nitrate) [undo]
  • Sitagliptin [undo]
  • Laboratory Scales I [undo]
  • EcoRI [undo]
  • Sugere que angariemos dinheiro. [undo]
  • El cântă. [undo]
  • The patient will be dissatisfied, and might not come to the next appointment and you will lose the follow up. You will also not have enough data about patient’s progress. [undo]
  • A [undo]
  • Semaglutide [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21124
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway